Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
Status:
Terminated
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the 4-month Progression-Free Survival (PFS), with
demonstrated increase in tumor doubling time, of eligible subjects treated with pazopanib
according to RECIST version 1.1 guidelines.